Prophase labs announces full uspto approval for issuance of u.s. patent protecting esophageal adenocarcinoma risk assessment

U.s. patent no. 12379378-b2 protects biomarker-driven systems and methods to assess progression risk in barrett's esophagus and esophageal adenocarcinoma; issuance follows the successful be-smart ™ test validation (>95% technical success) and, together with be-smart's demonstrated compatibility with both brush and forceps biopsies, supports earlier detection.
PRPH Ratings Summary
PRPH Quant Ranking